Healios K.K. (HLOSF)
USD 1.35
(0.0%)
USD 1.35
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -3.37 Billion JPY | -8477.62% |
| 2022 | -39.39 Million JPY | 15.72% |
| 2021 | -46.73 Million JPY | -14.95% |
| 2020 | -40.66 Million JPY | -3.22% |
| 2019 | -39.39 Million JPY | 99.22% |
| 2018 | -5.06 Billion JPY | -115.61% |
| 2017 | -2.34 Billion JPY | 33.05% |
| 2016 | -3.5 Billion JPY | -39689.14% |
| 2015 | -8.81 Million JPY | 98.45% |
| 2014 | -568.29 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -281 Million JPY | 73.16% |
| 2024 Q1 | -6.91 Million JPY | 3.15% |
| 2023 Q2 | -4.64 Million USD | 30.14% |
| 2023 FY | -3.37 Billion JPY | -8477.62% |
| 2023 Q4 | -7.66 Million USD | -53.87% |
| 2023 Q1 | -6.65 Million USD | 19.56% |
| 2023 Q3 | -4.97 Million USD | -7.1% |
| 2022 Q2 | -11.95 Million JPY | 99.16% |
| 2022 Q4 | -8.27 Million JPY | -16.16% |
| 2022 Q3 | -7.12 Million JPY | 40.42% |
| 2022 Q1 | -1.42 Billion JPY | 5.56% |
| 2022 FY | -39.39 Million JPY | 15.72% |
| 2021 FY | -46.73 Million JPY | -14.95% |
| 2021 Q2 | -9.33 Million JPY | 26.54% |
| 2021 Q4 | -1.51 Billion JPY | -5.66% |
| 2021 Q1 | -12.7 Million JPY | 98.99% |
| 2021 Q3 | -1.43 Billion JPY | -15220.05% |
| 2020 Q1 | -930 Million JPY | 25.36% |
| 2020 FY | -40.66 Million JPY | -3.22% |
| 2020 Q3 | -1.07 Billion JPY | -17.32% |
| 2020 Q2 | -918 Million JPY | 1.29% |
| 2020 Q4 | -1.25 Billion JPY | -16.71% |
| 2019 Q4 | -1.24 Billion JPY | -16.01% |
| 2019 Q3 | -1.07 Billion JPY | -5.5% |
| 2019 Q1 | -923 Million JPY | 10.39% |
| 2019 Q2 | -1.01 Billion JPY | -10.29% |
| 2019 FY | -39.39 Million JPY | 99.22% |
| 2018 Q1 | -553 Million JPY | -0.49% |
| 2018 Q3 | -732 Million JPY | 73.36% |
| 2018 Q2 | -2.74 Billion JPY | -396.93% |
| 2018 FY | -5.06 Billion JPY | -115.61% |
| 2018 Q4 | -1.03 Billion JPY | -40.71% |
| 2017 Q1 | -490 Million JPY | -7.86% |
| 2017 FY | -2.34 Billion JPY | 33.05% |
| 2017 Q2 | -445.39 Million JPY | 9.1% |
| 2017 Q4 | -550.3 Million JPY | 36.18% |
| 2017 Q3 | -862.28 Million JPY | -93.6% |
| 2016 Q2 | -488.09 Million JPY | 76.92% |
| 2016 FY | -3.5 Billion JPY | -39689.14% |
| 2016 Q4 | -454.3 Million JPY | -0.92% |
| 2016 Q3 | -450.16 Million JPY | 7.77% |
| 2016 Q1 | -2.11 Billion JPY | -496.03% |
| 2015 Q2 | -280.74 Million JPY | -20.7% |
| 2015 Q4 | -354.83 Million JPY | -84.58% |
| 2015 Q3 | -192.23 Million JPY | 31.53% |
| 2015 Q1 | -232.6 Million JPY | 0.0% |
| 2015 FY | -8.81 Million JPY | 98.45% |
| 2014 FY | -568.29 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -4607.046% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 68851.372% |
| SQZ Biotechnologies Company | -75.82 Million USD | -4356.314% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -18833.154% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 4228.187% |
| Mesoblast Limited | -84.14 Million USD | -3915.592% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -219879.962% |
| Genus plc | 6.4 Million USD | 52896.875% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 34783.236% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -362694.992% |
| Marizyme, Inc. | -34.08 Million USD | -9813.011% |
| ContraFect Corporation | -56.88 Million USD | -5839.637% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -40367.066% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -74086.68% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -240914.386% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -118440.316% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -122735.251% |
| MultiCell Technologies, Inc. | -722.81 USD | -467480980.782% |
| Accustem Sciences Inc. | -3.74 Million USD | -90092.795% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -5628.09% |
| EV Biologics, Inc. | -483.06 Thousand USD | -699396.131% |
| Q BioMed Inc. | -3.44 Million USD | -97966.645% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 95551.977% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -867266.584% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -128500.255% |
| Biomind Labs Inc. | -1 Million USD | -334586.01% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | -69148.274% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -50727.202% |
| Skye Bioscience, Inc. | -13.67 Million USD | -24615.107% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -169999.961% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -11281283.547% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -66884.07% |
| IMV Inc. | -38.67 Million USD | -8637.698% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -21192.098% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -174741.277% |
| GB Sciences, Inc. | -1.42 Million USD | -237772.481% |
| Alpha Cognition Inc. | -9.7 Million USD | -34714.949% |
| HST Global, Inc. | -140.9 Thousand USD | -2397935.584% |
| CSL Limited | 3.7 Billion USD | 191.275% |
| Halberd Corporation | -75.05 Thousand USD | -4502231.779% |
| Enzolytics Inc. | -2.14 Million USD | -157150.558% |
| Resverlogix Corp. | -12.74 Million USD | -26404.04% |
| Affymax, Inc. | -15.04 Million USD | -22357.796% |
| SYBLEU INC | -149.18 Thousand USD | -2264948.934% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -106551.129% |
| argenx SE | -425.04 Million USD | -694.967% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -5987.411% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -323559.004% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -213848.099% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -99137.029% |
| AVAX Technologies, Inc. | 6.69 Million USD | 50586.487% |
| Zenith Capital Corp. | -8.94 Million USD | -37683.741% |
| Genscript Biotech Corporation | -415.79 Million USD | -712.668% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -19396031.106% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -137519.705% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1970052.797% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -6046.726% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -116367.04% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -343275.814% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -181140.848% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -268928.662% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -168449.106% |
| BioStem Technologies, Inc. | -7.77 Million USD | -43337.633% |
| ONE Bio Corp. | 13.68 Million USD | 24797.496% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1861761.862% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -252926.925% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -300280.654% |
| Agentix Corp. | -1.37 Million USD | -246226.606% |
| LadRx Corporation | -3.82 Million USD | -88271.614% |
| Cell Source, Inc. | -4.32 Million USD | -78020.918% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -813178.168% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -491784.417% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -491784.417% |
| NovAccess Global Inc. | -2.46 Million USD | -136881.303% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -115641.216% |
| Itoco Inc. | -919.14 Thousand USD | -367526.259% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -79623.217% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -301866.041% |
| Kadimastem Ltd | -3.04 Million USD | -111042.176% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1290944.833% |
| CytoDyn Inc. | -18.05 Million USD | -18611.928% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -13424611.959% |
| Mobile Lads Corp. | -554.55 Thousand USD | -609222.874% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1535264.734% |
| Qrons Inc. | -643.67 Thousand USD | -524852.733% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -598246.446% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -151432.886% |
| Rebus Holdings, Inc. | -664 Thousand USD | -508785.542% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -185935.5% |
| International Stem Cell Corporation | -663 Thousand USD | -509553.092% |
| Bioxytran, Inc. | -3.82 Million USD | -88352.094% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -6418972.948% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -16612486.037% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -9217.267% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -208738.072% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -459106.208% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -108514.593% |
| Neutra Corp. | -229.48 Thousand USD | -1472320.976% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -19165.637% |
| PureTech Health plc | -146.19 Million USD | -2211.233% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -15622.773% |
| IXICO plc | -1.43 Million USD | -235042.658% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -35502.149% |
| Gelesis Holdings, Inc. | -121.8 Million USD | -2674.083% |
| CSL Limited | 3.81 Billion USD | 188.641% |
| Cellectis S.A. | -108.85 Million USD | -3004.062% |